Taishin Cloud and ITRI signed a cooperation MOU to create a complete process for AI applications and biomedical engineering, helping the biomedical industry to easily complete data analysis and model training.
The AI computing power wave is driving global industrial innovation and transformation. Taisun, leveraging its advantage as Asia's only commercial AI supercomputing service provider, is making its mark at the 2023 Asia Biotech Show. By integrating the computing power of the Taiwan Sugi-2 supercomputer with NVIDIA-optimized GPU computing frameworks, Taisun assists the biomedical industry in easily completing secondary gene analysis, drug development, medical imaging, and accelerated analysis. Furthermore, through federated learning technology and flexible, diversified cloud data storage solutions, Taisun drives the research and development and intelligent transformation of medical innovation technologies.
Wu Hanzhang, General Manager of ASUS Cloud and Taizhi Cloud, attended the event and said that Taizhi Cloud uses its AI supercomputing platform to accelerate the research and application of biomedical technologies and promote precision medicine.
Wu Han-chang, General Manager of ASUS Cloud and Taizhi Cloud, stated, "Since 2022, ASUS Group has been working with NVIDIA to assist the National Health Research Institutes in establishing the AI Biomedical Innovation Center, jointly promoting the significant development of AI computing power in the field of biotechnology. This collaboration with ITRI integrates the complete process of AI applications and biomedical engineering, meeting the needs for data processing, computing environment setup, AI biomedical model training, and technical tool development in one go, accelerating the research and application of biomedical technologies with an AI supercomputing platform."
Taizhiyun has launched OneAI, integrating healthcare industry needs with AI technology tools. This platform enables secondary gene analysis in just three steps without requiring coding, showcasing high efficiency and low barriers to entry. Taizhiyun's AI supercomputer utilizes the RAPIDS library, leveraging GPUs for high-efficiency processing of massive datasets, reducing training time from hours to minutes. This is further enhanced by the NVIDIA Clara™ for Drug Discovery deep learning algorithm, encompassing cheminformatics exploration, molecular dynamics simulation, protein structure prediction, and biomolecular structure exploration, accelerating new drug development. Secondary gene analysis employs high-output, high-precision NVIDIA® Parabricks® GPUs for acceleration, offering speeds up to 80 times faster than traditional CPU solutions while saving 50% in computational costs. Through the MONAI (Medical Open Network for AI) open-source deep learning framework, over 20 pre-trained medical image recognition models provide a 6x improvement in efficiency.
Taiwan Abrahams, together with ITRI, NHI, NVIDIA, and Taiwan Biotech, held the "AI Supercomputing and Biomedical Industry Integration Application Forum" to share the latest applications of integrating AI supercomputing and biomedical technology development.
At this year's Asia Biotech Show, Taiwan Abrahams, together with ITRI, NHI, NVIDIA, and Taiwan Biotech, hosted the "AI Supercomputing and Biomedical Industry Integration Application Forum" to share the latest applications of integrating AI supercomputing and biomedical technology development. They also signed a cooperation MOU with ITRI to optimize application solutions such as enzyme docking target technology and digital molecular screening technology, helping the biomedical industry to easily complete data analysis and model training, demonstrating Taiwan's technological capabilities in industry and research and its digital advantages in cross-industry integration.